Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DynPort Vaccine, a CSC company, has received a contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to establish and operate a Phase I clinical trial unit for infectious disease therapeutics.
Subscribe to our email newsletter
The contract is valued at approximately $32.3 million over a seven-year period. DynPort Vaccine (DVC) is teaming with Quintiles Transnational to complete this work.
Under the terms of the agreement, DVC and Quintiles will manage a Phase I clinical trial unit to assess the safety of investigational therapeutic products being studied by National Institute of Allergy and Infectious Diseases (NIAID), and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year.
As the prime contractor, DVC will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Work will be performed by DVC at its headquarters in Frederick, Maryland. Quintiles will provide Phase I clinical research and support services for the implementation and conduct of approved Phase I clinical trial protocols.
Trials will include therapeutic candidates for a broad range of infectious diseases. Investigational products tested could include measures to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
Oren Cohen, managing director of Quintiles’ Public Health and Government Services business, said: “Quintiles’ portion of the work on this contract will take place in our new, 150-bed Phase I clinical research unit in Overland Park, Kansas. The facility was dedicated in May 2007 and provides an ideal setting to perform multiple, concurrent clinical trials.”